Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study

BACKGROUND: Simlukafusp alfa (FAP-IL2v) was engineered to preferentially activate CD8+ T and natural killer (NK) cells in tumor microenvironments overexpressing fibroblast activation protein (FAP). Checkpoint inhibitors combined with antiangiogenic agents are standard therapy for metastatic renal cell carcinoma (mRCC), which overexpresses FAP. Here, we explored the efficacy, safety, and pharmacodynamic effects of FAP-IL2v in combination with atezolizumab with or without bevacizumab in patients with mRCC. METHODS: Patients with treatment-naïve or pretreated clear cell and/or sarcomatoid mRCC were eligible. Dose escalation explored FAP-IL2v every 2 weeks (Q2W) with atezolizumab Q2W (doublet, arm A), and with atezolizumab and bevacizumab Q2W (triplet, arm B) in patients treated with up to one prior systemic therapy. Dose extension explored in untreated patients the recommended FAP-IL2v dose administered Q2W (doublet, arm A; and triplet, arm B) or 3-weekly (doublet, arm C; and triplet, arm D). Primary objectives were the recommended FAP-IL2v dose and antitumor activity. Secondary objectives included safety, pharmacodynamics, and exploratory biomarkers in peripheral blood and paired biopsies. RESULTS: By the data cut-off date (31 August, 2021), 66 patients were enrolled. The median duration of treatment was 11.0 months. Objective response rates (ORRs) were 25% for the doublet and 47% for the triplet, and median progression-free survival was 6.3 and 18.3 months, respectively. Safety profiles were consistent with the individual drugs, including expected interleukin-2 (IL-2) class-specific adverse events (AEs). Two deaths were recorded caused by AEs related to study treatment (acute kidney injury, n=1; pancytopenia, n=1). Expansion and activation of NK and T cells, but not regulatory T cells, was observed in peripheral blood, leading to increased tumor infiltration and inflammation in paired biopsies. The addition of bevacizumab led to a reduced angiogenesis signature score and reduced vessel density. CONCLUSION: The combination of FAP-IL2v plus atezolizumab with or without bevacizumab was consistent with the known safety profile of the individual drugs. The maximum tolerated dose was not reached, with a recommended FAP-IL2v dose of 10 mg. ORR was higher among patients receiving the triplet therapy compared with the doublet. Pharmacodynamic results were consistent with the mechanism of action of IL-2, supporting further research in this field.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2026-04-01
DOI
https://doi.org/10.1136/jitc-2025-012466
Primary Topic
Peptidase Inhibition and Analysis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study

Carl Watson, Wei‐Yi Cheng, Víctor Moreno, A. Hussain et al.
Journal for ImmunoTherapy of Cancer
Peptidase Inhibition and Analysis
article

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study

Carl Watson, Wei‐Yi Cheng, Víctor Moreno, A. Hussain, Alice Julien-Laferrière, J.L. Perez-Gracia, Nassim Sleiman, T. Vardar, Aaron R. Hansen, Jorge Dorado Pérez, Christian Heichinger, Nino Keshelava, P. Pedrazzoli, Nicolas Staedler, David Dejardin, Se Hoon Park, Christophe Boetsch, Emilia Andersson, Jeffrey A. Sosman, Anton Kraxner, Jehad Charo, Volker Teichgräber, Mario Sznol, Cristina Suárez, C. Gomez-Roca, Begoña Mellado, Rikke Løvendahl Eefsen, Teresa Alonso-Gordoa, Caroline Ardeshir-Tandon, Tom Waddell, Alejo Rodriguez-Vida, Sylvie Negrier, Ana Patricia Silva, Jens Bedke, Thomas Powles, Jae-Lyun Lee, Lukasz Spychaj, Stefan Evers
article en

Abstract

BACKGROUND: Simlukafusp alfa (FAP-IL2v) was engineered to preferentially activate CD8+ T and natural killer (NK) cells in tumor microenvironments overexpressing fibroblast activation protein (FAP). Checkpoint inhibitors combined with antiangiogenic agents are standard therapy for metastatic renal cell carcinoma (mRCC), which overexpresses FAP. Here, we explored the efficacy, safety, and pharmacodynamic effects of FAP-IL2v in combination with atezolizumab with or without bevacizumab in patients with mRCC. METHODS: Patients with treatment-naïve or pretreated clear cell and/or sarcomatoid mRCC were eligible. Dose escalation explored FAP-IL2v every 2 weeks (Q2W) with atezolizumab Q2W (doublet, arm A), and with atezolizumab and bevacizumab Q2W (triplet, arm B) in patients treated with up to one prior systemic therapy. Dose extension explored in untreated patients the recommended FAP-IL2v dose administered Q2W (doublet, arm A; and triplet, arm B) or 3-weekly (doublet, arm C; and triplet, arm D). Primary objectives were the recommended FAP-IL2v dose and antitumor activity. Secondary objectives included safety, pharmacodynamics, and exploratory biomarkers in peripheral blood and paired biopsies. RESULTS: By the data cut-off date (31 August, 2021), 66 patients were enrolled. The median duration of treatment was 11.0 months. Objective response rates (ORRs) were 25% for the doublet and 47% for the triplet, and median progression-free survival was 6.3 and 18.3 months, respectively. Safety profiles were consistent with the individual drugs, including expected interleukin-2 (IL-2) class-specific adverse events (AEs). Two deaths were recorded caused by AEs related to study treatment (acute kidney injury, n=1; pancytopenia, n=1). Expansion and activation of NK and T cells, but not regulatory T cells, was observed in peripheral blood, leading to increased tumor infiltration and inflammation in paired biopsies. The addition of bevacizumab led to a reduced angiogenesis signature score and reduced vessel density. CONCLUSION: The combination of FAP-IL2v plus atezolizumab with or without bevacizumab was consistent with the known safety profile of the individual drugs. The maximum tolerated dose was not reached, with a recommended FAP-IL2v dose of 10 mg. ORR was higher among patients receiving the triplet therapy compared with the doublet. Pharmacodynamic results were consistent with the mechanism of action of IL-2, supporting further research in this field.

Journal for ImmunoTherapy of CancerVol. 14(4)
Université Claude Bernard Lyon 1 (FR), Ulsan College (KR), Roche (Switzerland) (CH), Hebron University (PS), University of Maryland, Baltimore (US), Queen Mary University of London (GB), Pfizer (United Kingdom) (GB), Barts Health NHS Trust (GB), University of Pavia (IT), Asan Medical Center (KR), Princess Alexandra Hospital (AU), Samsung Medical Center (KR), Copenhagen University Hospital (DK), Princess Margaret Cancer Centre (CA), Rigshospitalet (DK), Yale Cancer Center (US), University of Ulsan (KR), Centre Léon Bérard (FR), Roche (United Kingdom) (GB), Hospital Clínic de Barcelona (ES), University Children's Hospital Tübingen (DE), Vall d'Hebron Hospital Universitari (ES), Institut Claudius Regaud (FR), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Del Mar (ES), The Christie Hospital (GB), Clinica Universidad de Navarra (ES), Policlinico San Matteo Fondazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Klinikum Stuttgart (DE), Hospital Universitario Ramón y Cajal (ES), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, U-M Rogel Cancer Center (US), Universitat de Barcelona (ES)
Roche
Good health and well-being
Openalex Percentile: Top 20%
Peptidase Inhibition and Analysis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.